Bioo Scientific has announced the availability of colour endpoint assays that use a technology for the visible detection of in-vivo toxicity using only 5ul of serum from rodents or other mammals.
The Maxdiscovery Aspartate Transaminase (AST) and Lactate Dehydrogenase (LDH) assays are tools for the detection of drug-induced toxicity to the liver and heart can be used for preclinical testing in the drug discovery process.
These assays employ simplified endpoint analysis to offer high sensitivity, low detection limits and the ability to use a visible plate reader.
The Maxdiscovery Aspartate Transaminase (AST) kit permits quantitative visible determination of AST in a convenient format.
The Maxdiscovery LDH Color Endpoint Assay kit measures the direct chemical conversion of LDH and does not rely on coupled enzymatic amplification for high precision, quantitative measurements.
Each kit contains ready-to-use product standards for the development of standard curves and accurate calibration of the assay.
'Our AST and LDH kits will provide researchers with tools to identify toxic effects and adjust therapeutic formulations to minimise toxicity,' said Dr Joe Krebs, director of protein chemistry at Bioo.
